Search: WFRF:(Karlsson Ann Charlotte)
> (2015-2019) >
Differences in outc...
-
Karlsson, JohannesDepartment of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
(author)
Differences in outcome for cervical cancer patients treated with or without brachytherapy
- Article/chapterEnglish2017
Publisher, publication year, extent ...
-
Philadelphia, USA :Elsevier,2017
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:oru-53486
-
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-53486URI
-
https://doi.org/10.1016/j.brachy.2016.09.011DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Purpose: To compare the clinical outcome of cervical cancer patients treated with primary radiotherapy with and without the addition of brachytherapy.Methods and Materials: In all, 220 patients with cervical cancer stage I-IV treated between 1993 and 2009 were included. Three or five 6.0 Gy fractions of brachytherapy were given in addition to the external beam radiotherapy to 134 patients, whereas 86 patients received external beam radiotherapy alone (EBRTA). In the EBRTA group, the patients received external boost instead of brachytherapy with a total dose to the tumor of 64-72 Gy.Results: The 5-year overall survival and cancer-specific survival rates of the complete series were 42.5% and 55.5%, respectively. The rates of primary complete remission, 5-year cancer-specific survival, and recurrence were 92.5%, 68.5%, and 31.3% for the brachytherapy group vs. 73.3%, 35.4%, and 37.2% for the EBRTA group. The survival (all types) of the patients receiving brachytherapy was significantly (p < 0.0001) better than for the patients treated with external boost, but the difference was most pronounced in FIGO stage II tumors. Higher FIGO stage, nonsquamous cell carcinoma histology, treatment with EBRTA, and lower total equal 2-Gy (EQD2) external dose were significantly associated with poorer survival, lower rate of remission, and higher recurrence rate in multivariate models.Conclusions: Primary tumor remission rate, recurrence rate, and all types of survival rates were improved in the brachytherapy group. Brachytherapy is important to achieve sufficient doses to the periphery and central part of the tumor and should always be considered in treatment of cervical carcinomas.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Dreifaldt, Ann-Charlotte,1958-Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden(Swepub:oru)ledt
(author)
-
Bohr Mordhorst, Louise,1958-Örebro universitet,Institutionen för medicinska vetenskaper,Department of Oncology, Faculty of Health and Medical Sciences, Örebro University, Örebro, Sweden(Swepub:oru)lbt
(author)
-
Sorbe, Bengt,1947-Örebro universitet,Institutionen för hälsovetenskaper,Department of Oncology, Faculty of Health and Medical Sciences, Örebro University, Örebro, Sweden(Swepub:oru)bse
(author)
-
Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, SwedenInstitutionen för medicinska vetenskaper
(creator_code:org_t)
Related titles
-
In:BrachytherapyPhiladelphia, USA : Elsevier16:1, s. 133-1401538-47211873-1449
Internet link
Find in a library
To the university's database